Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2000

View Archived Issues

Watson to acquire Schein

Ivax to develop treatment for cystic fibrosis with CBR

Way to increase cord blood stem cell production discovered by Aastrom

deCODE Genetics establishes research agreement with Partners

Daiichi licenses Captisol technology from CyDex

CD40 agonist MAbs reduce disease severity in a mouse model of rheumatoid arthritis

ImClone Systems commences phase I trial of antiangiogenesis agent IMC-1C11

Intellivax and Active Biotech form partnership to develop streptococcal vaccine

Genentech's single-injection clot buster for heart attack approved by FDA

Immunomedics reports phase II results of CEA-Cide as colorectal cancer therapy

Vical's cationic lipid formulation selectively enhances antibody immune response to antigen pDNA

ASGT presentation documents enhanced antitumor activity for p53 attached to VP22

NDA submitted for fast-dissolving Zomig

Abarelix depot versus currently used therapies for prostate cancer: results of pivotal trials

Arimidex receives Canadian approval for treatment of advanced breast cancer

Anticholinergics in the pipeline at Sumitomo for urinary incontinence

New compounds from Sanofi-Synthelabo preferably contract urethral smooth muscle and veins

Novel 5-HT1A receptor ligands from SCRAS particularly useful in hypertension Rx

Benzimidazoles synthesized at Takeda act as GnRH antagonists

Calcium channel blockers in development at Questcor as neuroprotective agents

Series of heparin antagonist peptides described by Commonwealth Biotechnologies

Furopyridine antibacterials discovered by Pfizer

New GH secretagogues specifically claimed for use in type II diabetes

New expanded indication of Enbrel approved by FDA

Myriad Genetics identifies novel prostate cancer gene as part of Schering-Plough collaboration

Sangamo and R.W. Johnson establish collaborative research program

ISIS-3521 to be advanced to phase III trials for NSCLC based on recent results

Eos Biotechnology and Aventis Pasteur enter cancer vaccine agreement

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...